Monte Carlo Simulation

Using data from the 1000 Monte Carlo replicates, the mean Standard Deviation (SD) and median incremental cost-effectiveness ratios were US $2769/LYS (US $20,164) and US $1784/LYS, respectively, for RS-guided therapy compared to tamoxifen alone and US $3856/LYS (US $23,106) and US $4198 for chemotherapy plus tamoxifen compared to RS-guided therapy. As shown in Figure 4A, incremental cost-effectiveness ratios for the relationship between RS-guided therapy and tamoxifen alone are primarily represented by an increase in LYS while simultaneously associated with an increase in cost. As shown in Figure 4B, incremental cost-effectiveness ratios for the relationship between RS-guided therapy and the chemotherapy plus tamoxifen strategy demonstrate that the RS-guided therapy reduces estimated total treatment costs in 70% of the randomly drawn samples in Monte Carlo analysis with and an overall benefit in terms of life expectancy.

0 0

Post a comment